Shore Capital Appointed as Nominated Adviser and Sole Broker to Oxford BioDynamics Plc
Shore Capital has been appointed with immediate effect as Nominated Adviser and Sole Broker to Oxford BioDynamics Plc
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) (“Oxford BioDynamics”) is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange’s AIM under the ticker “OBD”. For more information please visit www.oxfordbiodynamics.com
Enquiries
|
Oxford BioDynamics Plc. |
|
+44 (0)1865 518910 |
|
Christian Hoyer Millar, CEO |
|
|
|
Paul Stockdale, CFO |
|
|
|
|
|
|
|
Shore Capital |
|
+44 (0)20 7408 4090 |
|
Stephane Auton |
|
|
|
Edward Mansfield |
|
|